Gemcitabine 200mg
| Product Overview | |
| Generic Name | Gemcitabine 200mg |
| Brand Name(s) | Gemzar |
| Form | IV Lyophilized powder for infusion |
| Strength | 200 mg |
| Therapeutic Class | Antimetabolite (pyrimidine analog) |
| ATC Code | L01BC05 |
| Manufacturing & Regulatory | |
| Manufacturer | Eli Lilly |
| Country | Canada, USA, India |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II/III |
| COFEPRIS | 010.000.6294.00 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Not publicly available as parallel traded molecule |
Description
Gemcitabine is an injectable chemotherapy medicine used under specialist oncology supervision for the treatment of several solid tumors, including pancreatic cancer, non-small cell lung cancer, ovarian cancer, breast cancer, and selected bladder or biliary tract cancers. It is administered by intravenous infusion, either alone or in combination with other chemotherapy agents, depending on the approved oncology protocol.
